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Introduction D-amino acid oxidase (DAO) is a peroxisomal flavoprotein that catalyzes with strict stereospecificity the oxidative deamination of neutral and polar D-amino acids to α -keto acids, NH 3 and hydrogen peroxide (H 2 O 2 ) (Angermüller et al., 2009 ). In the central nervous system (CNS), DAO is restricted to the lower brainstem, cerebellum and spinal cord, decreasing levels in the midbrain, the cortex and hippocampus (Horiike et al., 2001; Kapoor and Kapoor, 1997; Yoshikawa et al., 2004) .
Recently, we found that DAO gene deletion/mutation by using mutant ddY/DAO -/-mice (compared to ddY/DAO +/+ mice) and intravenous administration of the DAO inhibitor sodium benzoate significantly blocked the late phase flinch response (hyperalgesia) of the mouse formalin test. Intravenous administration of sodium benzoate did not affect the acute pain transmission such as in the early phase flinch response in the formalin test, or thermal nociceptive responses in the tail flick test or hot-plate test in mice (Zhao et al., 2008) . In agreement with our studies, another non-specific DAO inhibitor chlorpromazine (Yagi et al., 1956 ) was also reported to block formalin-induced hyperalgesia without affecting the early phase acute pain response (Li et al., 2000) .
Subcutaneous injection of formalin produces biphasic behavioral effects in rats, with the early phase reflecting an acute nociceptive state followed by the late phase reflecting a state of persistent hyperalgesia which involves central sensitization (Coderre et al., 1993; Jett et al., 1997) . Central sensitization is an increase in This article has not been copyedited and formatted. The final version may differ from this version. The results with sodium benzoate suggest that DAO may contribute to central sensitization-mediated pain transmission. Neuropathic pain remains one of the most challenging of all neurological conditions and presents a large unmet need for improved therapies. Central sensitization is fundamental to the development of neuropathic pain (Hulsebosch et al., 2009) . It is thus possible that DAO is involved in neuropathic pain which shares the common mechanism of central sensitization with formalin-induced hyperalgesia.
The aim of this present study is to determine the potential role of DAO in neuropathic pain in a rat model of tight L5/L6 spinal nerve ligation. Tight ligation of L5 and L6 spinal nerves in rats produces mechanical allodynia and heat hyperalgesia mediated by central sensitization, representing characteristic neuropathic pain syndromes in humans (Kim and Chung, 1992; Jett et al., 1997) . This study included the following procedures: 1) examining expression and activity changes of the spinal DAO, as well as development of neuropathic pain (mechanical allodynia) following L5/L6 spinal nerve ligation; 2) testing the analgesic actions of the competitive DAO inhibitor sodium benzoate by systemic injection in neuropathic rats; 3) further determining whether systemic administration of sodium benzoate exerts its analgesic effect through inhibition of spinal DAO activity by measuring spinal DAO activity and testing the analgesic effect of intrathecally injected sodium benzoate. The inhibitory effect of sodium benzoate was also confirmed in the rat formalin test and compared to the rat acute nociceptive model in this study. The preliminary result of guidelines of the National Institutes of Health. Animals were acclimated to the laboratory environment for 5-7 days before entering the study. Experimental study groups were assigned in random and the researcher was blind for behavior testing.
The rat model of neuropathic pain. The unilateral ligation of two spinal nerves (L5/L6) was performed under intraperitoneal pentobarbital anesthetized (50 mg/kg) rats as described earlier (Kim and Chung, 1992; Wei et al., 2007) . Briefly, left L5
and L6 spinal nerves were isolated and tightly ligated with 6-0 silk thread.
Following ligation, the wound was sutured and the rats were allowed to recover. In SHAM-operated rats the same surgical procedure except for spinal nerve isolation and This article has not been copyedited and formatted. The final version may differ from this version. The rat formalin test. Rats were acclimated individually to the observation cage for 30 min prior to testing. The formalin test was performed by injecting 100 µl of 5% formalin (in 0.9% saline) subcutaneously on the dorsal side of the left hind paw as previously described (Wang et al., 2000) and the rat was immediately placed in a 23 cm × 35 cm × 19 cm transparent polycarbonate box. Nociceptive behavior was quantified by counting numbers of formalin-injected paw flinches in 1-min epochs.
Measurements were taken at 10-min intervals beginning immediately after formalin injection and ending 90 minutes later.
The rat tail flick test. The model SSY-H digital display thermostatic water-bath (Shanghai Sanshen Medical Instrument CO., Ltd., Shanghai, China) was used to maintain a constant water temperature of 50 ± 0.5 ºC. While being placed in a tubular restrainer, the tail of the rat was immersed 5 cm in the water bath as previously described (Wang et al., 2000) . expression and activity (to a less degree) were in agreement with the time-course of mechanical allodynia development (Fig. 1) .
Effects of intraperitoneal injection of sodium benzoate on neuropathic pain, hyperalgesia and nociceptive pain. The effect of sodium benzoate on mechanical allodynia was examined in L5/L6 spinal nerve ligated rats 10-14 days after surgery.
Three groups of neuropathic rats (n = 8 in each group) received intraperitoneal injections of normal saline (4 ml/kg), sodium benzoate (400 mg/kg), and morphine The effect of sodium benzoate on hyperalgesia was tested in the rat formalin test.
Three groups of rats (n = 8) received intraperitoneal injection of normal saline (4 ml/kg), sodium benzoate (400 mg/kg), and morphine (10 mg/kg), respectively.
Subcutaneous injection of 5% formalin (100 µl) was then received 30 minutes later.
Subcutaneous injection of formalin in normal saline-treated control rats produced a characteristic biphasic flinch responses consisting of an early phase (within 10 minutes after formalin injection), followed by a slowly rising and long-lasting (10~90 min) late phase (i.e., hyperalgesia). As shown in benzoate did not affect thermal nociceptive thresholds or produce motor side effects (Fig. 2C) .
Inhibition of systemic sodium benzoate on spinal DAO activity. DAO activity in the lumbar enlargement of the spinal cord was measured to determine whether systemic administration of sodium benzoate exerted its analgesic effect through inhibiting DAO activity in the spinal cord. Rats (n = 6 in each group) were sacrificed and the lumbar enlargements of the spinal cord were prepared 60 and 120 minutes after intraperitoneal injection of normal saline (4 ml/kg) or sodium benzoate (400 mg/kg). The enzymatic activity was assayed by measuring pyruvate production from DAO-catalyzed D-alanine oxidation. Intraperitoneal administration of sodium benzoate at 400 mg/kg significantly inhibited DAO activity in the lumbar spinal cord measured at both 60 and 120 minutes after drug administration (Fig. 3) . SEP-227900, a DAO inhibitor of unknown structure, was reportedly in early stage clinical investigation for the treatment of neuropathic pain (Williams, 2009 ).
Effects of intrathecal injection
The present findings confirmed our and other laboratories' reports where DAO inhibitors blocked formalin-induced hyperalgesia in rats (Li et al., 2000) and mice (Zhao et al., 2008) . In addition, we recently expanded the finding by intrathecal administration of a more potent and selective DAO inhibitor AS057278 that blocked formalin-induced hyperalgesia in a dose-dependent manner in rats (Gao et al., Central sensitization reflects an increase in excitability of spinal and brain neurons following persistent nociceptive stimulation resulting from nerve injuries and/or inflammation (Cook et al., 1987; Woolf et al., 1994) . Our observed specific analgesia produced by sodium benzoate suggest that DAO is involved in central (spinal) sensitization in pain, as both employed pain models (spinal nerve ligation-induced neuropathic pain and formalin-induced hyperalgesia) are generally believed to be mediated by central sensitization (Kim and Chung, 1992; Coderre et al., 1993; Jett et al., 1997) . The mechanism for this is not known. It is well noted that certain level of D-Serine is present in the CNS and D-Serine binds to and activates strychnine-insensitive glycine sites associated with N-methyl-daspartate (NMDA)
receptors (Schell et al., 1995; Ying-Luan et al., 2007) . Activation of NMDA receptors is considered to be a major contributor to central sensitization-maintained pain that involve inflammation and/or nerve injury (Petrenko et al., 2003; Ying-Luan et al., 2007) . Hashimoto et al. (1993) showed that the concentration of D-Serine was higher in the CNS in ddY/DAO-/-mice lacking DAO activity. Furthermore, NMDA receptor-mediated synaptic transmission and formalin-induced hyperalgesia were exaggerated in ddY/DAO-/-mice lacking DAO activity (Wake et al., 2001 ). These (Pollegioni et al., 2007) , D-alanine (Moreno et al., 1999) , and glycine (De Marchi and Johnston, 1969) . Spinal H 2 O 2 has been reported to be involved in central sensitization-mediated pain states including neuropathic pain (Hacimuftuoglu et al., 2006; Kim et al., 2004 Kim et al., , 2006 Lee et al., 2007; Viggiano et al., 2005) . Further studies are warranted to explore exact mechanisms for algesic action of spinal DAO.
Known inhibitors of DAO include benzoic acid (sodium benzoate), chlorpromazine, pyrrole and potassium sorbate. Sodium benzoate is a common food preservative and has been used in the treatment of patients with inborn errors of urea synthesis in order to facilitate the alternative pathway of nitrogen waste excretion (Kubota and Ishizaki, 1991) . It has also been shown to be a competitive inhibitor of DAO in vitro and can efficiently attenuate DAO mediated functions in vivo (Moses et al., 1996; Williams and Lock, 2005; Wu et al., 2006; Xin et al., 2007) . Sodium benzoate is widely given in high doses (such as 100-1000 mg/kg) by systemic administration for blockade of DAO activity without reporting non-specific related biological effects (Moses et al., 1996; Williams and Lock, 2005; Wu et al., 2006; Xin et al., 2005 Xin et al., , 2007 , due to its low potency (mM in IC50 values) and rapid excretion in urine (Kubota and Ishizaki, 1991; MacArthur et al., 2004; Xin et al., 2007) . It is reasonable to speculate that the analgesic action of sodium benzoate may result from its possible non-specific effect 
